PROVENTION BIO INC's ticker is PRVB and the CUSIP is 74374N102. A total of 108 filers reported holding PROVENTION BIO INC in Q2 2020. The put-call ratio across all filers is 0.21 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $41,753,395 | +26.8% | 1,732,506 | -44.4% | 0.00% | +100.0% |
Q4 2022 | $32,941,152 | +465.5% | 3,116,476 | +140.8% | 0.00% | – |
Q3 2022 | $5,825,000 | +20.4% | 1,294,425 | +7.0% | 0.00% | – |
Q2 2022 | $4,837,000 | -48.2% | 1,209,189 | -5.1% | 0.00% | – |
Q1 2022 | $9,331,000 | +36.9% | 1,274,666 | +5.1% | 0.00% | – |
Q4 2021 | $6,815,000 | -25.3% | 1,212,710 | -14.9% | 0.00% | – |
Q3 2021 | $9,125,000 | -18.5% | 1,425,738 | +7.3% | 0.00% | -100.0% |
Q2 2021 | $11,198,000 | -1.7% | 1,328,337 | +22.4% | 0.00% | 0.0% |
Q1 2021 | $11,393,000 | -32.5% | 1,085,609 | +9.0% | 0.00% | 0.0% |
Q4 2020 | $16,872,000 | +27.3% | 995,965 | -3.6% | 0.00% | 0.0% |
Q3 2020 | $13,256,000 | +8.5% | 1,033,239 | +19.4% | 0.00% | 0.0% |
Q2 2020 | $12,214,000 | +6839.8% | 865,599 | +4431.9% | 0.00% | – |
Q1 2020 | $176,000 | -48.1% | 19,100 | -16.0% | 0.00% | – |
Q4 2019 | $339,000 | +189.7% | 22,730 | +32.9% | 0.00% | – |
Q3 2019 | $117,000 | – | 17,100 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
DG Capital Management, LLC | 287,172 | $4,052,000 | 3.32% |
Johnson & Johnson Innovation - JJDC, Inc. | 1,124,973 | $15,873,000 | 3.12% |
Perceptive Advisors | 4,525,711 | $63,858,000 | 1.04% |
683 Capital Management, LLC | 600,000 | $8,467,000 | 0.68% |
Monashee Investment Management LLC | 250,000 | $3,528,000 | 0.53% |
Soleus Capital Management, L.P. | 59,900 | $845,000 | 0.48% |
EAM Global Investors LLC | 69,564 | $982,000 | 0.44% |
EAM Investors, LLC | 54,020 | $762,000 | 0.17% |
Virtus ETF Advisers LLC | 24,401 | $344,000 | 0.16% |
GILDER GAGNON HOWE & CO LLC | 1,251,260 | $17,655,000 | 0.14% |